How to Label Investigational Products for Global Clinical Trials: Best Practices

Labeling investigational products (IP) for global study sites is one of the most critical and complex aspects of clinical trial supply management. Labels must meet country-specific regulatory guidelines while ensuring subject safety, blinding integrity, and traceability. In this tutorial, we cover the essential steps and best practices for designing and implementing compliant IP labels across international clinical sites.

The Purpose and Scope of IP Labeling:

Investigational product labels provide key information to study participants and site personnel. They help ensure correct usage, blinding, and storage of the product throughout the study. As per USFDA and EMA guidance, improper labeling is a major regulatory concern and can jeopardize trial integrity.

Core Objectives of IP Labeling:

• Compliance with local regulatory requirements
• Ensuring participant safety
• Maintaining the blind and randomization codes
• Facilitating traceability and accountability

Standard Content Required on IP Labels:

While specific content may vary by region, several universal elements are expected in any IP label:

• Protocol number and study title
• Unique product code or identifier
• Randomization/blinding codes (if applicable)
• Storage conditions (e.g., “Store between 2°C–8°C”)
• Expiry or retest date
• Dosage instructions or cautionary statements
• Site address or shipment location
• Statements like “For Clinical Trial Use Only”

Global Regulatory Labeling Requirements:

Labeling requirements vary across regulatory jurisdictions. It is essential to harmonize them while customizing for country-specific elements.

Examples of Country-Specific Labeling Rules:

1. USFDA: IP label must include sponsor information and the IND number.
2. CDSCO (India): Requires labeling in English and Hindi or local language, along with approval reference numbers.
3. EMA: Dual language labeling may be mandatory for EU countries. Storage and expiry must be prominently displayed.

To learn how regulatory expectations impact label stability, visit Stability Studies.

Multilingual Labeling and Translation:

Labels in multinational trials must often be printed in multiple languages to meet local requirements. However, the risk of translation errors must be mitigated through validated processes.

Best Practices for Translation:

• Use qualified, professional medical translators
• Apply back-translation techniques for verification
• Involve local regulatory experts to confirm accuracy
• Document all translation workflows for audit readiness

Label Design and Blinding Considerations:

Designing IP labels involves not just compliance, but also maintaining blinding and logistical efficiency. For blinded studies, labels must not disclose treatment group or product identifiers.

Design Strategies for Blinded Labels:

• Use identical labels for active and placebo products
• Assign anonymized kit codes with randomization systems
• Include barcodes or QR codes for digital tracking
• Use tamper-evident label materials

For aligning with GMP principles during labeling, see GMP documentation.

Label Printing, Inspection, and Reconciliation:

Once label text and layout are approved, printing must follow validated processes. Each batch should undergo a thorough inspection before use.

Checklist for Labeling Operations:

1. Approved label text version in system
2. Quality-approved label template and format
3. Validated label printers and software
4. Reconciliation of printed vs. used labels
5. Destruction log for unused/damaged labels

Label Accountability at Site Level:

Study sites must log all IP label usage, including receipt, application, and destruction. Site Initiation Visits (SIVs) must include label SOP training.

Ensure compliance with SOP writing in pharma to meet site accountability standards.

Label Change Control and Documentation:

Any change in IP label text, layout, or format requires a documented change control. All changes must be approved by QA and tracked using version control.

Documenting Label Changes:

• Initiate change request with justification
• Assess regulatory implications
• Update label version and inform all sites
• Archive superseded label versions securely

Quality Assurance and Regulatory Audits:

Regulatory bodies such as ANVISA and MHRA expect complete traceability and compliance in labeling practices. Regular audits ensure that sponsor and site practices align with GCP and GMP.

Audit Readiness Tips:

• Maintain version-controlled label files
• Archive all translation validations
• Retain batch-specific label reconciliation records
• Document training records for label-related SOPs

Conclusion:

Effective investigational product labeling across global study sites requires meticulous planning, regulatory understanding, and operational control. By standardizing label content, maintaining multilingual accuracy, and integrating QA oversight, sponsors can ensure compliance and trial success. Leveraging best practices also minimizes the risk of regulatory findings, safeguarding both data integrity and patient safety.